Matinas BioPharma Holdings (MTNB) Change in Receivables (2015 - 2017)

Matinas BioPharma Holdings (MTNB) reported Change in Receivables of -$5.0 for Q3 2017, up 99.99% quarter-over-quarter from -$79809.0 in Q4 2015.

Matinas BioPharma Holdings (MTNB) Change in Receivables (2015 - 2017) Analysis & Trends

Matinas BioPharma Holdings (MTNB) has 2 years of Change in Receivables data on file, last reported at -$5.0 in Q3 2017.

Change in Receivables for Q3 2017 came in at -$5.0, changed N/A year-over-year; the trailing twelve-month figure through Sep 2017 was -$5.0 (up 99.99% YoY), and the FY2015 annual result was -$45643.0, changed N/A from the prior year.
Change in Receivables rose to -$5.0 in Q3 2017 per MTNB's latest filing, from -$79809.0 in the prior quarter.
Over five years, Change in Receivables peaked at $29748.0 in Q2 2015 and troughed at -$79809.0 in Q4 2015.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Change in Receivables (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	22,529.00
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	-
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	-39.80 Mn
9	Abivax	91.96 Bn	91.96 Bn	-	-4.08 Mn
10	Matinas BioPharma Holdings	4.60 Mn	2.15 Mn	-	-

Download Data